Teva Settles With Pfizer Over Xeljanz XR As 2025 Date Looms
Israeli Firm Previously Sued Over Patent Expiring In 2034
Teva has opted against litigating with Pfizer over its controversial Xeljanz XR JAK inhibitor, settling patent infringement proceedings over a US patent scheduled to expire in 2034. Zydus Cadila recently bagged 180 days of exclusivity for a strength of its ANDA product.
